别名 整合素α4、alpha 4 subunit of VLA-4 receptor、antigen CD49D + [8] |
简介 Integrins alpha-4/beta-1 (VLA-4) and alpha-4/beta-7 are receptors for fibronectin. They recognize one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. They are also receptors for VCAM1. Integrin alpha-4/beta-1 recognizes the sequence Q-I-D-S in VCAM1. Integrin alpha-4/beta-7 is also a receptor for MADCAM1. It recognizes the sequence L-D-T in MADCAM1. On activated endothelial cells integrin VLA-4 triggers homotypic aggregation for most VLA-4-positive leukocyte cell lines. It may also participate in cytolytic T-cell interactions with target cells. ITGA4:ITGB1 binds to fractalkine (CX3CL1) and may act as its coreceptor in CX3CR1-dependent fractalkine signaling (PubMed:23125415). ITGA4:ITGB1 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1 (PubMed:18635536, PubMed:25398877). |
靶点 |
作用机制 CD49d拮抗剂 |
在研机构 |
在研适应症 |
非在研适应症- |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2023-08-24 |
靶点 |
作用机制 CD49d拮抗剂 |
在研机构 |
原研机构 |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2004-11-23 |
靶点 |
作用机制 CD49d拮抗剂 |
在研机构 |
原研机构 |
在研适应症 |
非在研适应症- |
最高研发阶段临床2/3期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
开始日期2024-12-01 |
开始日期2023-10-27 |
申办/合作机构 |
开始日期2023-07-07 |
申办/合作机构 |